Organics processing firm says its ReCirculate food waste-content potting soil and compost will be available in retail stores ...

Fred Sousa, VP of retail sales at Denali, will join Louise Fritjofsson, CEO and co-founder of Martie Inc., for a session on ...

Denali, the nation’s leading recycler of organics, today introduced ReCirculate – its compost and organic potting soil ...

A car rebuild expert found a GMC Sierra Denali with a salvage title, sitting abandoned in an auction yard, looking pathetic. The pickup truck is listed as damaged by fire, but was it really ...

Sanofi (NASDAQ:SNY) has failed in another mid-stage trial for DNL788, an experimental therapy developed with Denali Therapeutics (NASDAQ:DNLI) for neurological conditions such as amyotrophic ...

VAN BUREN -- A lawsuit filed Friday in Crawford County seeks to require Denali Water Solutions to cease operation at its storage lagoon until its "noxious odors and harmful emissions" are eliminated.

The pair climbed Denali and sampled microplastics along their route in June, 2024. (Photo by Roger Jaramillo) Two mountaineers who are also University of Alaska Fairbanks students were successful ...

Related: Up Close With the 2024 GMC Sierra EV Denali Edition 1 There is one major development for the 2025 GMC Sierra EV: The introduction of a new, smaller battery. That this smaller pack is ...

The 2025 GMC Sierra EV Denali has popped up on the company's website. It's the only 2025 model listed, and it offers nearly $10,000 in savings versus the sold-out 2024 Edition 1. GMC has released ...

The 2024 GMC Sierra EV Denali Edition 1 is still a rare sight on US roads, but that hasn’t stopped GM from rolling out the 2025 version with up to 440 miles of range … and a base price that ...

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report)’s stock price traded down 3.8% on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $29.00 to $28.00.

On Friday, Denali Therapeutics Inc. (NASDAQ:DNLI) maintained its Buy rating from TD Cowen, despite recent clinical trial results. The phase 2 study evaluating DNL788, a small molecule RIPK1 inhibitor, ...